Format

Send to

Choose Destination
Am J Ophthalmol. 2003 Oct;136(4):737-9.

Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema.

Author information

1
Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33101, USA. iscott@bpei.med.miami.edu

Abstract

PURPOSE:

To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME).

DESIGN:

Interventional case series.

METHODS:

Two patients with ICME were treated with intravitreal triamcinolone.

RESULTS:

In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 microm before and 197 microm posttreatment in the right eye and 542 microm before and 190 microm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 microm before and 208 microm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients.

CONCLUSIONS:

Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.

PMID:
14516818
DOI:
10.1016/s0002-9394(03)00266-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center